DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
email sent successfully
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
DUBLIN–(BUSINESS WIRE)–Apr. 10, 2023– Horizon Therapeutics plc (Nasdaq: HZNP) today announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of adults with chronic TED and low CAS, which is a measure of disease activity. The totality of clinical trial data continues to strongly support the efficacy of TEPEZZA across a broad spectrum of TED patients regardless of disease activity or duration, with a well-established safety profile. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of TED – a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease.1
Evidence & EducationGenetic Associations of the Thyroid Stimulating Hormone Receptor Gene With Graves’ Diseases and Graves’ ...Graves' disease (GD) is a common thyroid...
Evidence & EducationPsychological Symptoms and Thyroid DisordersPeople with thyroid disorders often have...
Evidence & EducationAssociation of Radioactive Iodine Treatment With Cancer Mortality in Patients With HyperthyroidismImportance Radioactive iodine (RAI) h...
Evidence & EducationGraves’ Disease Following Immune Reconstitution or Immunomodulatory Treatment: Should We Manage it any Differe...Graves' disease and other disorders of t...
Videos & VisualsThyroid Glandhttps://www.niddk.nih.gov/-/media/Images...
Evidence & EducationNew Therapeutic Horizons for Graves’ HyperthyroidismGraves’ hyperthyroidism is characteriz...
Evidence & EducationPatients’ Perceptions and Views of Surgery and Radioiodine Ablation in the Definitive Management of GravesR...Background: Patients' perceptions and p...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.